Alphamab Oncology is a biopharmaceutical company focused on research, development, manufacturing, and commercialization of cancer biotherapeutics in China. Its pipeline includes PD-L1 inhibitors, HER2-targeting bispecific antibodies, and ADC programs across multiple solid tumor indications.
Alphamab Oncology dosed the first patient in its Phase III trial of JSKN003, a biparatopic HER2-targeting antibody-drug conjugate, for HER2-positive advanced colorectal cancer on February 14, 2026.
Alphamab Oncology has dosed the first patient in a Phase III study of JSKN003, a biparatopic HER2-targeting ADC, for HER2-positive advanced colorectal cancer. The drug demonstrated a 68.8% response rate in earlier trials.
